Abstract
We have used the bone marrow micronucleus assay (BMMN) as a measure of clastogenicity, in response to etoposide exposure in murine bone marrow. Oral delivery of etoposide resulted in a reduced number of micronucleated polychromatic erythrocytes (MPE) relative to the same dose delivered intraperitoneally (P < 0.001). Daily fractionation of the oral schedule of etoposide led to a more than six-fold increase in cumulative MPE frequency over that observed with the same total, unfractionated dose, with the potency of the response increasing with serial exposure (r = 0.79). Retrovirally-mediated expression of MDR1 in murine bone marrow resulted in partial protection against the clastogenic activity of etoposide relative to mock transduced control mice. The model system developed has indicated a variety of factors able to influence the genotoxicity of etoposide. It should now be possible to further exploit this model in order to define other factors governing haemopoietic sensitivity to etoposide.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pizzo PA, Poplack DG (eds). General principles of chemotherapy. In: Principles and Practice of Paediatric Oncology 2nd edn. Lippincott-Raven: Philadelphia, Chapter 1:9 1997 pp 215–272
Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF . Non-intercalative antitumour drugs interfere with the breakage reunion of mammalian DNA topoisomerase II J Biol Chem 1984 259: 13560–13566
Ross W, Rowe T, Glisson B, Yalowich J, Liu L . Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage Cancer Res 1984 44: 5857–5860
Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kolm KW . Topoisomerase II mediated DNA breaks and cytotoxicity in relation with proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukaemia cells Cancer Res 1987 47: 2050–2055
Pommier Y, Kerrigan D, Civey JM, Kao-Shan C, Whang-Peng J . Sister chromatid exchanges, chromosomal aberrations and cytotoxicity produced by antitumour topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells Cancer Res 1988 48: 512–516
Chatterjee S, Trivedi D, Petzold SJ, Berger NA . Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines Cancer Res 1990 50: 2713–2718
Hunger SP, Tkachuk DC, Amylon MD, Link MP, Carroll AJ, Welborn JL, Willman CL, Cleary ML . HRX involvement in de novo and secondary leukaemias with diverse chromosome 11q23 abnormalities Blood 1993 81: 3197–3203
Ratain MJ, Kaminer LS, Bitran JD . Actue non-lymphocytic leukaemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung Blood 1987 70: 1412–1417
Pederson-Bjergaard J, Daugaard J, Daugaard G, Hansen SW . Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin and bleomycin for germ-cell tumours Lancet 1991 338: 359–363
Nichols CR, Breeden SE, Loehrer PJ . Secondary leukaemia associated with a conventional dose of etoposide: review of serial germ cell tumour protocols J Natl Cancer Inst 1993 85: 36–40
Bjorin DF, Motzer RJ, Rodriguez E . Acute non-lymphocytic leukaemia in germ cell tumour patients treated with etoposide-containing chemotherapy J Natl Cancer Inst 1993 85: 60–62
Hawkins MM, Wilson NMK, Stovall MA, Marsden HB, Potok MHN, Kingston JE, Chessels JM . Epipodophyllotoxins, alkylating agents and radiation risk of secondary leukaemia after childhood cancer BMJ 1992 304: 951–958
Pui C-H, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund GT, Crist WM . Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia New Engl J Med 1991 325: 1682–1687
Wang L, Setlow R . Inactivation of O6-alkylguanine-DNA-alkyltransferase in HeLa cells by cisplatin Carcinogenesis 1989 10: 1681–1684
Trey J, Gerson S . The role of O6-alkylguanine-DNA-alkyltransferase in limiting nitrosourea-induced sister chromatid exchanges in proliferating human lymphocytes Cancer Res 1989 49: 1899–1903
Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD . Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute non-lymphocytic leukaemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7 J Clin Oncol 1986 4: 325–345
Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanen GR . Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide J Clin Oncol 1993 11: 209–217
Van Os R, Robinson S, Sheridan T, Mislow JMK, Dawes D, Mauch PM . Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents Blood 1998 92: 1950–1956
Rafferty JA, Hickson I, Chinnasamy N, Lashford LS, Margison GP, Dexter TM, Fairbairn LJ . Chemoprotection of normal tissues by transfer of drug resistance genes Cancer Metastasis Rev 1996 15: 365–383
Scmid W . The micronucleus test Mutat Res 1975 31: 9–15
Rafferty JA, Lashford LS, Turner SD, Fairbairn LJ . Genetic chemoprotection of bone marrow from the dose-limiting toxicities of chemotherapy Prog Growth Fact 1999 5: 3–7
Tinwell H, Ashby J . Comparison of acridine orange and giesma stains in several mouse bone marrow studies including a triple dose experiment Mutagenesis 1989 4: 477–482
Hyashi M, Morita T, Kodama Y, Sofuni T, Ishidate M . The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange coated slides Mutat Res 1990 245: 245–249
Eckert H, Stockschlader M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum C . High dose multidrug resistance in primary human hematopoietic cells transduced with optimized retroviral vectors Blood 1996 88: 3407–3415
Fairbairn LJ, Lashford LS, Spooncer E, McDermott RH, Lebens G, Arrand LE, Arrand JR, Bellantuono I, Holt R, Hatton CE, Cooper A, Besley GTN, Wriath JE, Anson DS, Hopwood JJ, Dexter TM . Long-term in vitro correction of α-iduronidase deficiency (Hurler syndrome) in human bone marrow Proc Natl Acad Sci USA 1996 93: 2025–2030
Chinnasamy N, Rafferty JA, Hickson I, Lashford LS, Longhurst SJ, Thatcher N, Margison GP, Dexter TM, Fairbairn LJ . Chemoprotective gene transfer II: multilineage in vitro protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase Gene Therapy 1998 5: 842–847
Han YM, Yoo OJ, Lee KK . Sex determination in single mouse blastomeres by polymerase chain reaction J Assist Reprod Genet 1993 10: 151–156
UKCCSG Chemotherapy Standardisation Working Group 1994 Personal communication: L Lashford
Davidson A, Gowing R, Lowis L, Newell D, Lewis I, Dicks-Mireaux C, Pinkerton CR . Phase II study of 21 day oral etoposide in children. New agents group of the United Kingdoms Childrens Cancer Study Group (UKCCSG) Eur J Cancer 1997 33: 1816–1822
Clark PL, Cottier B . The activity of 10, 14 and 21 day schedules of single agent etoposide in previously untreated patients with extensive SCLC Semin Oncol 1992 19: (Suppl. 14) 36–39
Bertholt F . University of Cologne, Germany. Personal communication
Singh SP, McCoy MT, Tice RR, Schneider EL . A simple technique for quantitation of low levels of DNA damage in individual cells Exp Cell Res 1988 175: 184–191
Hoorn AJW, Custer LL, Myhr BC, Brusick D, Gossen J, Vigj J . Detection of chemical mutagens using MutaMouse: a transgenic mouse model Mutagenesis 1993 8: 7–10
Ashby J, Tinwell H, Glover P, Poorman-Allen P, Krehl R, Callander RD, Clive D . Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses Environ Mol Mutagen 1994 24: 51–60
Larripa IB, Carballo MA, Mudry MM, Laball de Vinusa L . Etoposide and teniposide: in vitro and in vivo genotoxicity studies Drug Invest 1992 4: 365–375
Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J . Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide Cancer Treat Rep 1985 69: 269–273
Collaborative Study Group for the Micronucleus Test, The Mammalian Mutagenesis Study Group of the Environmental Mutagen Society, Japan (CSGMT/JEMS . MMS). Single vs multiple dosing in the micronucleus test: the summary of the fourth collaborative study by CSGMT/JEMS.MMS Mutat Res 1990 234: 205–222
Hayashi M, Sofuni T, Morita T . Simulation study of the effects of multiple treatments in the mouse bone marrow micronucleus test Mutat Res 1991 252: 281–287
Hofland K, Peterson BO, Helin K, Jensen PB, Sehested M . Response of cellular DNA topoisomerases to induction of full length E2F-1/DP-1 transcription factor Proc Am Assoc Cancer Res 1997 38: 62
Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID . Physiological regulation of eukaryotic topoisomerase II Biochim Biophys Acta 1998 1400: 121–137
Wright EG . Radiation-induced genomic instability in haemopoietic cells Int J Radiat Biol 1998 74: 681–687
Spiers AD . Multiple drug resistance, the MDR gene, and the law of maximum perversity as it applies to oncology: an hypothesis Haematol Oncol 1994 12: 155–161
Acknowledgements
SDT is in receipt of an MRC studentship award and a Zeneca case award. Research undertaken in the Paterson Institute was supported by the Cancer Research Campaign (UK) and the NHS Research and Development Levy. CB is funded by the Deutsche Krebshilfe (10–1456 Ba2). We thank L Woolford, M Willington and T McNally for technical assistance and Prof OB Eden for his generous support and advice.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Turner, S., Rafferty, J., Fairbairn, L. et al. The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow. Leukemia 14, 1796–1802 (2000). https://doi.org/10.1038/sj.leu.2401810
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401810